pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

STAT's The Readout LOUD podcast goes international with a Shanghai dispatch on China's biotech surge

Sep 24, 2026·read at STAT ↗Neutral

The Readout LOUD podcast, part of STAT's weekly biotech series, is expanding its reach beyond the United States this week. Host Jason Mast reports from Shanghai, where he examines how China's growing drug development capabilities are influencing the global biotech landscape.

The episode includes commentary on the FDA's so-called Overton era, highlighting recent regulatory shifts and their impact on companies worldwide. The discussion also touches on the broader implications for investors and drug developers as Chinese firms accelerate their pipelines.

The piece is authored by Elaine Chen, Adam Feuerstein and Allison DeAngelis, who each bring expertise in biotech trends, regulatory changes and financing of emerging startups.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “The FDA’s Overton era, and dispatches from Shanghai”

read at STAT ↗
565 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GILEAD
drugs
Obesity2DisPATCHImmunology
topics
Immunology2Obesity2Cell TherapyHematologyOncology

related stories

  • Dec 23Fierce Biotech Layoff Tracker 2026: BMS slashes 265 HQ roles; Novo reveals 4k more employees were laid offFierce Biotech
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • 1d agoNovo workforce down 13,000BioSpace
  • 2d ago2026 IPO blitz continues with 4 new biotech filingsBioSpace
  • Aug 26Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialBioPharma Dive